|1.||Wang, Chunxiu: 2 articles (02/2015 - 08/2014)|
|2.||Lei, Lijun: 2 articles (02/2015 - 08/2014)|
|3.||Troxler, Thomas: 2 articles (02/2015 - 08/2014)|
|4.||Perrone, Mark: 2 articles (02/2015 - 08/2014)|
|5.||Auberson, Yves P: 2 articles (02/2015 - 08/2014)|
|6.||Yang, Charles R: 2 articles (02/2015 - 08/2014)|
|7.||Liu, Yu-Chih: 2 articles (02/2015 - 08/2014)|
|8.||Zhang, Xuechun: 2 articles (02/2015 - 08/2014)|
|9.||Wang, Tie-Lin: 2 articles (02/2015 - 08/2014)|
|10.||Feuerbach, Dominik: 2 articles (02/2015 - 08/2014)|
|1.||Parkinson Disease (Parkinson's Disease)
01/01/1985 - "Both ergolines and ergopeptines are used in treatment of Parkinson's disease and their therapeutic efficacy, as well as their propensity to develop undesirable side effects is under investigation. "
04/01/2011 - "Observational studies addressing the frequency of moderate or severe valvular regurgitation among ergoline-treated patients with Parkinson's disease were considered for a meta-analysis. "
08/01/2006 - "Ergoline and non-ergoline derivatives in the treatment of Parkinson's disease."
01/01/2001 - "The tetracyclic ergoline derivative cabergoline was investigated in three studies to test its efficacy in treating the motor symptoms of Parkinson's disease. "
05/01/2014 - "Non-ergoline dopamine agonists (DA) are effective treatments for Parkinson's disease (PD). "
01/01/1979 - "Nitrosourea derivatives of ergolines have been synthesized for the purpose of obtaining agents with both prolactin-and tumor-inhibitory activity. "
01/01/1977 - "Ergolines as potential prolactin and mammary tumor inhibitors."
11/01/1983 - "Correlation between inhibitory effect on prolactin secretion and antitumor activity of new ergoline compounds on DMBA-induced tumors in rats."
09/01/1984 - "The effect of the new, prolactin-lowering ergoline derivative FCE21336 and medroxyprogesterone acetate (MPA) given alone and in combination was tested on DMBA-induced mammary tumors in rats. "
11/01/1977 - "Those ergot compounds and ergolines that proved to be highly effective in reducing tumor size or in inducing regression of tumors to nonpalpability were Deprenon (D-6-methyl-8-ergolin-I-ylacetic acid amide) and ergocryptine; effective to an intermediate degree were Dironyl [N-(D-6-methyl-8-isoergolin-I-yl)-N',N'-diethylurea], ergocornine, and Lysenyl [N-(D-6-methyl-8-isoergolenyl)-N',N'-diethyl-urea]; and effective to a minimal degree were Lergotrile (2-chloro-6-methylergoline-8beta-acetonitrile), CB-154, and 6605-VUFB (D-6-methyl-8-cyanomethylergolin-I). "
08/01/2014 - "It displays favorable pharmacokinetic and in vitro safety profiles, and served as a lead compound in a program to explore ergoline derivatives as potential drug candidates for the treatment of narcolepsy. "
08/01/2014 - "Ergoline-derived inverse agonists of the human h3 receptor for the treatment of narcolepsy."
02/01/2015 - "From ergolines to indoles: improved inhibitors of the human H3 receptor for the treatment of narcolepsy."
|1.||Dopamine Agonists (Dopamine Agonist)